Hologic, Inc.

NasdaqGS:HOLX

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🔬 Clinical Trials

💻 Telehealth

Location

United States

Market Cap

USD 14.37 B

Share Price

USD 64.48

Avg Daily Volume

3,673,441

Change (1 day)

0.80%

Change (1 year)

-10.71%

Change (YTD)

-10.56%

Hologic, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 29, 2025: 25.28%

Hologic, Inc. EBITDA Margin is 25.28% for the Trailing 12 Months (TTM) ending March 29, 2025, a 0.81% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Hologic, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 30, 2024 was 25.08%, a -24.64% change year over year.
Hologic, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending April 01, 2023 was 33.28%, a -27.36% change year over year.
Hologic, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 26, 2022 was 45.81%, a -14.83% change year over year.
Hologic, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 27, 2021 was 53.79%, a 94.61% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA Margin	Net Income Margin	EBT Margin	Operating Income Margin

NasdaqGS: HOLX

Hologic, Inc.

CEO	Mr. Stephen P. MacMillan
IPO Date	March 1, 1990
Location	United States
Headquarters	250 Campus Drive
Employees	7,063
Sector	🏥 Health Care
Industries Medical Instruments 🔬 Clinical Trials 💻 Telehealth

Description

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.